11 May 2021 (Tuesday) - BTLP-TACT Excercise

Time for another BTLP-TACT exercise.
I was presented with one case – a nineteen year old female requiring twenty-eight weeks blood group antibody screening.

She grouped as AB Rh(D) Positive with antibody screen positive in all three cells so I requested antibody panels.
The IAT panel was positive in cells 1, 3, 5, 6, 9 and 10 which looks like anti-E and anti Fy(a) but could not exclude anti-Cw

The enzyme panel was positive in cells 3 and 5 which corresponded with the anti-E 

The problem here is the anti-Cw. I would expect it in the enzyme panel… it wasn’t there. Have I excluded it… No.

I got the green light…

7 May 2021 (Friday) - ASH Update

 

The American Society of Hematology sent a spotlight on clotting disorders today:

High- and Low-Dose Rivaroxaban Versus Aspirin for Women With VTE and Heavy Menstrual Bleeding Results published in Research and Practice in Thrombosis and Haemostasis show no statistically significant difference in menstrual hemorrhage in patients with VTE who are treated with rivaroxaban at 10 mg or 20 mg, compared with aspirin.

Reduced Calf Muscle Pump Function Predicts VTE and Mortality Risk According to a study published in Blood, reduced calf pump function appears to be a risk factor for venous thromboembolism and an independent predictor of all-cause mortality.

How I Treat VTE in Pregnancy Saskia Middeldorp, MD, PhD, and Wessel Ganzevoort, MD, PhD, discuss the diagnosis, treatment, and prevention of venous thromboembolism in pregnant women.

 

6 May 2021 (Thursday) - Oncologist Newsletter

The nice people at “The Oncologist” sent their update today. Much of it went right over my head but some of it sunk in…

	Table of Contents: Vol 26, Issue 5 Full Issue

Selections From This Issue:

Commentaries Global Precision Oncology: A Call to Action Maheetha Bharadwaj, Mounica Vallurupalli, Franklin W. Huang Precision Medicine Clinic: Molecular Tumor Board Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20 Chiho Miyagawa, Hisamitsu Takaya, Kazuko Sakai et al. Advertisement

Clinical Trial Results Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer Thomas J. George, Alison M. Ivey, Azka Ali et al. Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma Aleksei Viktorovich Novik, Svetlana Anatolievna Protsenko, Irina Alexandrovna Baldueva et al.

Articles Weekly Paclitaxel‐Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response Hannah C. Timmins, Tiffany Li, Terry Trinh et al. Clinicopathologic and Genomic Characterization of PD‐L1 Positive Urothelial Carcinomas Richard S.P. Huang, James Haberberger, Lukas Harries et al. Treatment Outcomes of Well‐Differentiated High‐Grade Neuroendocrine Tumors Alex J. Liu, Benjamin E. Ueberroth, Patrick W. McGarrah et al.

Advertisement Effect of Concomitant PPI and Cabozantinib on Outcomes in Metastatic RCC Elie Rassy, Luigi Cerbone, Edouard Auclin et al. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with ICIs Jacqueline T. Brown, Yuan Liu, Julie M. Shabto et al.

Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia Douglas Tremblay, Noa Rippel, Jonathan Feld et al. An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced HCC Yu‐Yun Shao, Ann‐Lii Cheng, Chih‐Hung Hsu Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies Andrew W. Swartz, Jan Drappatz FDA Approval: Atezolizumab and Durvalumab Combined with Platinum‐Based Chemotherapy in Extensive Stage SCLC Luckson Mathieu, Sujay Shah, Lee Pai‐Scherf et al.

See the Full Issue